To the Editor We read with great interest the study by Falandry and colleagues in JAMA Oncology.1 When treating older patients with cancer, it is challenging when standard therapy cannot be implemented owing to low physical and organ reserve, even if performance status is good. The physician may reduce the dose and number of drugs when the patient is considered too vulnerable to receive standard therapy. This decision depends on the physician’s judgment. Therefore, a method is needed to distinguish between patients who have good tolerance to standard therapy and those who do not. In this study,1 the authors identified vulnerable patients based on the Geriatric Vulnerability Score (GVS) and examined whether single-agent carboplatin was better for this population than the standard doublet regimen. However, the completion rate and prognosis of the carboplatin arm did not exceed those of the control arm.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kosaka M, Mizutani T, Ishiki H. What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer? JAMA Oncol. 2021;7(11):1725–1726. doi:10.1001/jamaoncol.2021.4125
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.